Real-World Use of Prophylactic Anakinra to Mitigate CRS and Icans In CAR-T Therapy

Key Points

• Prophylactic anakinra significantly reduces the incidence of cytokine release syndrome and ICANS, enhancing patient safety.
• The analysis involved clinical evaluations of CAR-T therapy in patients receiving anakinra treatment, which showed notable outcomes.
• Evidence shows a reduction in adverse events associated with CAR-T therapy, particularly with respect to IL-6 mediated effects.
• Results highlight the potential of using anakinra in CAR-T therapy, calling for further validation in larger cohorts.